

# Remi A Nout

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1442501/publications.pdf>

Version: 2024-02-01

105  
papers

8,167  
citations

87401

40  
h-index

56606

87  
g-index

105  
all docs

105  
docs citations

105  
times ranked

6469  
citing authors

#	ARTICLE	IF	CITATIONS
1	Defining Substantial Lymphovascular Space Invasion in Endometrial Cancer. <i>International Journal of Gynecological Pathology</i> , 2022, 41, 220-226.	0.9	27
2	Impact of Vaginal Symptoms and Hormonal Replacement Therapy on Sexual Outcomes After Definitive Chemoradiotherapy in Patients With Locally Advanced Cervical Cancer: Results from the EMBRACE-I Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 112, 400-413.	0.4	20
3	Radiation Therapy Techniques and Treatment-Related Toxicity in the PORTEC-3 Trial: Comparison of 3-Dimensional Conformal Radiation Therapy Versus Intensity-Modulated Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 112, 390-399.	0.4	12
4	Severity and Persistency of Late Gastrointestinal Morbidity in Locally Advanced Cervical Cancer: Lessons Learned From EMBRACE-I and Implications for the Future. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 112, 681-693.	0.4	14
5	Risk Factors for Late Persistent Fatigue After Chemoradiotherapy in Patients With Locally Advanced Cervical Cancer: An Analysis From the EMBRACE-I Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 112, 1177-1189.	0.4	6
6	Dose-effect relationship between vaginal dose points and vaginal stenosis in cervical cancer: An EMBRACE-I sub-study. <i>Radiotherapy and Oncology</i> , 2022, 168, 8-15.	0.3	11
7	Tertiary lymphoid structures critical for prognosis in endometrial cancer patients. <i>Nature Communications</i> , 2022, 13, 1373.	5.8	47
8	A systematic review and meta-analysis of adjuvant chemotherapy after chemoradiation for locally advanced cervical cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 172, 103638.	2.0	8
9	Single vocal cord irradiation for early-stage glottic cancer: Excellent local control and favorable toxicity profile. <i>Oral Oncology</i> , 2022, 127, 105782.	0.8	7
10	Automated causal inference in application to randomized controlled clinical trials. <i>Nature Machine Intelligence</i> , 2022, 4, 436-444.	8.3	8
11	Persistence of Late Substantial Patient-Reported Symptoms (LAPERS) After Radiochemotherapy Including Image Guided Adaptive Brachytherapy for Locally Advanced Cervical Cancer: A Report From the EMBRACE Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 161-173.	0.4	16
12	Dose-Volume Effects and Risk Factors for Late Diarrhea in Cervix Cancer Patients After Radiochemotherapy With Image Guided Adaptive Brachytherapy in the EMBRACE I Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 688-700.	0.4	31
13	Importance of the ICRU bladder point dose on incidence and persistence of urinary frequency and incontinence in locally advanced cervical cancer: An EMBRACE analysis. <i>Radiotherapy and Oncology</i> , 2021, 158, 300-308.	0.3	23
14	Long-Term Toxicity and Health-Related Quality of Life After Adjuvant Chemoradiation Therapy or Radiation Therapy Alone for High-Risk Endometrial Cancer in the Randomized PORTEC-3 Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 975-986.	0.4	20
15	Management of oligo-metastatic and oligo-recurrent cervical cancer: A pattern of care survey within the EMBRACE research network. <i>Radiotherapy and Oncology</i> , 2021, 155, 151-159.	0.3	13
16	Abstract IA004: Challenges for future adjuvant studies and the role of immunotherapy in endometrial cancer. , 2021, , .		0
17	Prevalence and Prognosis of Lynch Syndrome and Sporadic Mismatch Repair Deficiency in Endometrial Cancer. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1212-1220.	3.0	47
18	Evaluation of treatment effects in patients with endometrial cancer and <i>POLE</i> mutations: An individual patient data meta-analysis. <i>Cancer</i> , 2021, 127, 2409-2422.	2.0	62

#	ARTICLE	IF	CITATIONS
19	Adjuvant Systemic Therapy after Chemoradiation and Brachytherapy for Locally Advanced Cervical Cancer: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2021, 13, 1880.	1.7	12
20	Highlights from the recent 2020 Annual Global IGCS Meeting. <i>Gynecologic Oncology</i> , 2021, 161, 333-335.	0.6	0
21	Risk factors and dose-effects for bladder fistula, bleeding and cystitis after radiotherapy with imaged-guided adaptive brachytherapy for cervical cancer: An EMBRACE analysis. <i>Radiotherapy and Oncology</i> , 2021, 158, 312-320.	0.3	33
22	Response to Yuce Sari et al.. <i>Radiotherapy and Oncology</i> , 2021, 158, 323-324.	0.3	0
23	Uterine serous carcinoma. <i>Gynecologic Oncology</i> , 2021, 162, 226-234.	0.6	58
24	Phase II study of definitive chemoradiation for locally advanced squamous cell cancer of the vulva: An efficacy study. <i>Gynecologic Oncology</i> , 2021, 163, 117-124.	0.6	11
25	An anthropomorphic deformable phantom of the vaginal wall and cavity. <i>Biomedical Physics and Engineering Express</i> , 2021, 7, 055019.	0.6	0
26	Risk factors for nodal failure after radiochemotherapy and image guided brachytherapy in locally advanced cervical cancer: An EMBRACE analysis. <i>Radiotherapy and Oncology</i> , 2021, 163, 150-158.	0.3	12
27	Defining the role of high-dose radiation in oligometastatic & oligorecurrent cervical cancer.. <i>Indian Journal of Medical Research</i> , 2021, 154, 303-318.	0.4	1
28	Late, Persistent, Substantial, Treatment-Related Symptoms After Radiation Therapy (LAPERS): A New Method for Longitudinal Analysis of Late Morbidity Applied in the EMBRACE Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 106, 300-309.	0.4	22
29	Recommendations from gynaecological (GYN) GEC-ESTRO working group ACROP: Target concept for image guided adaptive brachytherapy in primary vaginal cancer. <i>Radiotherapy and Oncology</i> , 2020, 145, 36-44.	0.3	32
30	Incorporation of molecular characteristics into endometrial cancer management. <i>Histopathology</i> , 2020, 76, 52-63.	1.6	163
31	Interpretation of somatic <i>POLE</i> mutations in endometrial carcinoma. <i>Journal of Pathology</i> , 2020, 250, 323-335.	2.1	203
32	Clinicopathological and molecular characterisation of "multiple classifier" endometrial carcinomas. <i>Journal of Pathology</i> , 2020, 250, 312-322.	2.1	205
33	Efficacy and toxicity of postoperative external beam radiotherapy or chemoradiation for early-stage cervical cancer. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1878-1886.	1.2	12
34	Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy. <i>Journal of Clinical Oncology</i> , 2020, 38, 3388-3397.	0.8	398
35	Phantom-based quality assurance for multicenter quantitative MRI in locally advanced cervical cancer. <i>Radiotherapy and Oncology</i> , 2020, 153, 114-121.	0.3	15
36	Evidence-Based Dose Planning Aims and Dose Prescription in Image-Guided Brachytherapy Combined With Radiochemotherapy in Locally Advanced Cervical Cancer. <i>Seminars in Radiation Oncology</i> , 2020, 30, 311-327.	1.0	32

#	ARTICLE	IF	CITATIONS
37	Education and training for image-guided adaptive brachytherapy for cervix cancerâ€”The (GEC)-ESTRO/EMBRACE perspective. <i>Brachytherapy</i> , 2020, 19, 827-836.	0.2	22
38	Implementing an online radiotherapy quality assurance programme with supporting continuous medical education â€” report from the EMBRACE-II evaluation of cervix cancer IMRT contouring. <i>Radiotherapy and Oncology</i> , 2020, 147, 22-29.	0.3	21
39	Definitive radiotherapy with image-guided adaptive brachytherapy for primary vaginal cancer. <i>Lancet Oncology</i> , The, 2020, 21, e157-e167.	5.1	39
40	Prognostic Integrated Image-Based Immune and Molecular Profiling in Early-Stage Endometrial Cancer. <i>Cancer Immunology Research</i> , 2020, 8, 1508-1519.	1.6	45
41	Initiatives for education, training, and dissemination of morbidity assessment and reporting in a multiinstitutional international context: Insights from the EMBRACE studies on cervical cancer. <i>Brachytherapy</i> , 2020, 19, 837-849.	0.2	6
42	Plan-library supported automated replanning for online-adaptive intensity-modulated proton therapy of cervical cancer. <i>Acta OncolÃ³gica</i> , 2019, 58, 1440-1445.	0.8	16
43	Selecting Adjuvant Treatment for Endometrial Carcinoma Using Molecular Risk Factors. <i>Current Oncology Reports</i> , 2019, 21, 83.	1.8	22
44	Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 1273-1285.	5.1	305
45	Reporting of Late Morbidity After Radiation Therapy in Large Prospective Studies: A Descriptive Review of the Current Status. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 957-967.	0.4	17
46	Importance of training in external beam treatment planning for locally advanced cervix cancer: Report from the EMBRACE II dummy run. <i>Radiotherapy and Oncology</i> , 2019, 133, 149-155.	0.3	12
47	Efficacy and toxicity of chemoradiation with image-guided adaptive brachytherapy for locally advanced cervical cancer. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 257-265.	1.2	18
48	MRI-driven design of customised 3D printed gynaecological brachytherapy applicators with curved needle channels. <i>3D Printing in Medicine</i> , 2019, 5, 8.	1.7	28
49	Reproducibility of lymphovascular space invasion (LVSI) assessment in endometrial cancer. <i>Histopathology</i> , 2019, 75, 128-136.	1.6	32
50	Image-guided Adaptive Radiotherapy in Cervical Cancer. <i>Seminars in Radiation Oncology</i> , 2019, 29, 284-298.	1.0	47
51	Letter to the editor regarding â€œA systematic review comparing radiation toxicity after various endorectal techniquesâ€. <i>Brachytherapy</i> , 2019, 18, 564.	0.2	1
52	Importance of Technique, Target Selection, Contouring, Dose Prescription, and Dose-Planning in External Beam Radiation Therapy for Cervical Cancer: Evolution of Practice From EMBRACE-I to II. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 885-894.	0.4	39
53	Ovarian function after ovarian transposition and additional pelvic radiotherapy: A systematic review. <i>European Journal of Surgical Oncology</i> , 2019, 45, 1328-1340.	0.5	40
54	Predictive factors for response and toxicity after brachytherapy for rectal cancer; results from the HERBERT study. <i>Radiotherapy and Oncology</i> , 2019, 133, 176-182.	0.3	22

#	ARTICLE	IF	CITATIONS
55	Frequent Homologous Recombination Deficiency in High-grade Endometrial Carcinomas. <i>Clinical Cancer Research</i> , 2019, 25, 1087-1097.	3.2	113
56	Implementation of state-of-the-art (chemo)radiation for advanced cervix cancer in the Netherlands: A quality improvement program. <i>Technical Innovations and Patient Support in Radiation Oncology</i> , 2019, 9, 1-7.	0.6	4
57	Adjuvant therapy for high-risk endometrial cancer: recent evidence and future directions. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 51-60.	1.1	12
58	Molecular Classification of Grade 3 Endometrioid Endometrial Cancers Identifies Distinct Prognostic Subgroups. <i>American Journal of Surgical Pathology</i> , 2018, 42, 561-568.	2.1	214
59	Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 295-309.	5.1	426
60	The EMBRACE II study: The outcome and prospect of two decades of evolution within the GEC-ESTRO GYN working group and the EMBRACE studies. <i>Clinical and Translational Radiation Oncology</i> , 2018, 9, 48-60.	0.9	415
61	Investigators' response. <i>Lancet Oncology</i> , The, 2018, 19, 602.	5.1	0
62	Adjuvant Treatment for <i>POLE</i> Proofreading Domain Mutant Cancers: Sensitivity to Radiotherapy, Chemotherapy, and Nucleoside Analogues. <i>Clinical Cancer Research</i> , 2018, 24, 3197-3203.	3.2	50
63	Benefit of adaptive CT-based treatment planning in high-dose-rate endorectal brachytherapy for rectal cancer. <i>Brachytherapy</i> , 2018, 17, 78-85.	0.2	3
64	Endorectal Brachytherapy Boost After External Beam Radiation Therapy in Elderly or Medically Inoperable Patients With Rectal Cancer: Primary Outcomes of the Phase 1 HERBERT Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 908-917.	0.4	59
65	Clinical implementation of coverage probability planning for nodal boosting in locally advanced cervical cancer. <i>Radiotherapy and Oncology</i> , 2017, 123, 158-163.	0.3	21
66	Ki-67 in endometrial cancer: scoring optimization and prognostic relevance for window studies. <i>Modern Pathology</i> , 2017, 30, 459-468.	2.9	53
67	Amplification of 1q32.1 Refines the Molecular Classification of Endometrial Carcinoma. <i>Clinical Cancer Research</i> , 2017, 23, 7232-7241.	3.2	37
68	Reply to M. Wissing et al. <i>Journal of Clinical Oncology</i> , 2017, 35, 1862-1862.	0.8	0
69	Final results of the international randomized PORTEC-3 trial of adjuvant chemotherapy and radiation therapy (RT) versus RT alone for women with high-risk endometrial cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 5502-5502.	0.8	23
70	Limited impact of intratumour heterogeneity on molecular risk assignment in endometrial cancer. <i>Oncotarget</i> , 2017, 8, 25542-25551.	0.8	15
71	Microsatellite instability derived <i>JAK1</i> frameshift mutations are associated with tumor immune evasion in endometrioid endometrial cancer. <i>Oncotarget</i> , 2016, 7, 39885-39893.	0.8	29
72	ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-up. <i>International Journal of Gynecological Cancer</i> , 2016, 26, 2-30.	1.2	515

#	ARTICLE	IF	CITATIONS
73	Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer—Combined Analysis of the PORTEC Cohorts. <i>Clinical Cancer Research</i> , 2016, 22, 4215-4224.	3.2	535
74	Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 1114-1126.	5.1	135
75	Dose—effect relationship and risk factors for vaginal stenosis after definitive radio(chemo)therapy with image-guided brachytherapy for locally advanced cervical cancer in the EMBRACE study. <i>Radiotherapy and Oncology</i> , 2016, 118, 160-166.	0.3	153
76	Long-Term Health-Related Quality of Life in Patients With Rectal Cancer After Preoperative Short-Course and Long-Course (Chemo) Radiotherapy. <i>Clinical Colorectal Cancer</i> , 2016, 15, e93-e99.	1.0	19
77	Health-Related Quality of Life in Locally Advanced Cervical Cancer Patients After Definitive Chemoradiation Therapy Including Image Guided Adaptive Brachytherapy: An Analysis From the EMBRACE Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 94, 1088-1098.	0.4	77
78	Prognostic significance of L1CAM expression and its association with mutant p53 expression in high-risk endometrial cancer. <i>Modern Pathology</i> , 2016, 29, 174-181.	2.9	68
79	A comprehensive longitudinal overview of health-related quality of life and symptoms after treatment for rectal cancer in the TME trial. <i>Acta Oncologica</i> , 2016, 55, 502-508.	0.8	44
80	<i>POLE</i> Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 3347-3355.	3.2	249
81	Rectal bleeding after radiation therapy for endometrial cancer. <i>Radiotherapy and Oncology</i> , 2015, 115, 240-245.	0.3	7
82	No Increased Risk of Second Cancer After Radiotherapy in Patients Treated for Rectal or Endometrial Cancer in the Randomized TME, PORTEC-1, and PORTEC-2 Trials. <i>Journal of Clinical Oncology</i> , 2015, 33, 1640-1646.	0.8	83
83	ESMO—ESGO—ESTRO consensus conference on endometrial cancer: Diagnosis, treatment and follow-up. <i>Radiotherapy and Oncology</i> , 2015, 117, 559-581.	0.3	167
84	Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer — A pooled analysis of PORTEC 1 and 2 trials. <i>European Journal of Cancer</i> , 2015, 51, 1742-1750.	1.3	273
85	Nomograms for Prediction of Outcome With or Without Adjuvant Radiation Therapy for Patients With Endometrial Cancer: A Pooled Analysis of PORTEC-1 and PORTEC-2 Trials. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 91, 530-539.	0.4	59
86	Prognostic Significance of POLE Proofreading Mutations in Endometrial Cancer. <i>Journal of the National Cancer Institute</i> , 2015, 107, 402.	3.0	229
87	Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative. <i>Modern Pathology</i> , 2015, 28, 836-844.	2.9	343
88	Long-Term Impact of Endometrial Cancer Diagnosis and Treatment on Health-Related Quality of Life and Cancer Survivorship: Results From the Randomized PORTEC-2 Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 797-809.	0.4	96
89	Bowel Function 14 Years After Preoperative Short-Course Radiotherapy and Total Mesorectal Excision for Rectal Cancer: Report of a Multicenter Randomized Trial. <i>Clinical Colorectal Cancer</i> , 2015, 14, 106-114.	1.0	231
90	Health related quality of life and patient reported symptoms before and during definitive radio(chemo)therapy using image-guided adaptive brachytherapy for locally advanced cervical cancer and early recovery — A mono-institutional prospective study. <i>Gynecologic Oncology</i> , 2015, 136, 415-423.	0.6	46

#	ARTICLE	IF	CITATIONS
91	Adjuvant chemotherapy and radiation therapy (RT) versus RT alone for women with high-risk endometrial cancer: Toxicity and quality-of-life results of the randomized PORTEC-3 trial.. Journal of Clinical Oncology, 2015, 33, 5501-5501.	0.8	2
92	In Reply. Oncologist, 2014, 19, 1208-1208.	1.9	0
93	In Reply to Whitley etÂal. International Journal of Radiation Oncology Biology Physics, 2014, 90, 469-470.	0.4	0
94	Health-related quality of life 14years after preoperative short-term radiotherapy and total mesorectal excision for rectal cancer: Report of a multicenter randomised trial. European Journal of Cancer, 2014, 50, 2390-2398.	1.3	80
95	Primary Ewing sarcoma of the iris. Lancet, The, 2014, 383, 256.	6.3	2
96	High concordance of molecular tumor alterations between pre-operative curettage and hysterectomy specimens in patients with endometrial carcinoma. Gynecologic Oncology, 2014, 133, 197-204.	0.6	70
97	Manifestation Pattern of Early-Late Vaginal Morbidity After Definitive Radiation (Chemo)Therapy and Image-Guided Adaptive Brachytherapy for Locally Advanced Cervical Cancer: An Analysis From the EMBRACE Study. International Journal of Radiation Oncology Biology Physics, 2014, 89, 88-95.	0.4	106
98	Posttraumatic Stress Disorder After High-Dose-Rate Brachytherapy for Cervical Cancer With 2 Fractions in 1 Application Under Spinal/Epidural Anesthesia: Incidence and Risk Factors. International Journal of Radiation Oncology Biology Physics, 2014, 89, 260-267.	0.4	68
99	Improved risk assessment of endometrial cancer by combined analysis of MSI, PI3K&Aacute;AKT, Wnt/Î2-catenin and P53 pathway activation. Gynecologic Oncology, 2012, 126, 466-473.	0.6	60
100	Five-year quality of life of endometrial cancer patients treated in the randomised Post Operative Radiation Therapy in Endometrial Cancer (PORTEC-2) trial and comparison with norm data. European Journal of Cancer, 2012, 48, 1638-1648.	1.3	141
101	Long-Term Outcome and Quality of Life of Patients With Endometrial Carcinoma Treated With or Without Pelvic Radiotherapy in the Post Operative Radiation Therapy in Endometrial Carcinoma 1 (PORTEC-1) Trial. Journal of Clinical Oncology, 2011, 29, 1692-1700.	0.8	221
102	The Role of Radiotherapy in Endometrial Cancer: Current Evidence and Trends. Current Oncology Reports, 2011, 13, 472-478.	1.8	42
103	Point: Vaginal brachytherapy should be a standard adjuvant treatment for intermediate-risk endometrial cancer. Brachytherapy, 2011, 10, 1-3.	0.2	5
104	Rebuttal to Drs. Reed and Harrand. Brachytherapy, 2011, 10, 7.	0.2	1
105	Quality of Life After Pelvic Radiotherapy or Vaginal Brachytherapy for Endometrial Cancer: First Results of the Randomized PORTEC-2 Trial. Journal of Clinical Oncology, 2009, 27, 3547-3556.	0.8	253